Case

(ID)

Age

(Ans)

Sex

E

Consultation time

(Months)

OMS Performance index

Tumor site

Histological type

Expressed antibodies

Expression of KI67

Classification (TNM)

Treatment

Quality of resection

Evolution

Rattrapage

1

36

M

12

1

Trigon

High grade neuroendocrine carcinoma

CD56, Synaptophysine Chromogranine

70%

T4N1M1                (peritoneum)

Chemotherapy (1 Cycle of Etoposide-Carboplatine)

NA

PDV

NA

2

68

M

3

1

Postéro-basal wall

Small cell neuroendocrine carcinoma

CD56, CK(AE3,AE1), Synaptophysine Chromogranine

90%

T4N1M1                (peritoneum/Skin)

NA

NA

DCD

NA

3

65

M

2

1

Trigon

Large cell neuroendocrine carcinoma

CKAE3, Synaptophysine Chromogranine

65%

T4N1M1                      (Poumon)

NA

NA

Refusal of treatment

NA

4

73

M

7

0

Postéro-basal wall

Poorly differentiated carcinoma with neuroendocrine component

Synaptophysine Chromogranine

75%

T3N1M0

Chemotherapy (Gemzar-Carboplatine)

NA

PDV

NA

5

63

M

12

1

Antero-lateral wall

Small cell neuroendocrine carcinoma

CD56, Chromogranine, CK7

85%

T3N1M0

Chemotherapy (4 Cycles of Etoposide-CDDP)

NA

Encephalic Progression

NA